Sucampo Pharmaceuticals (SCMP) Misses Q4 Revenue Forecasts

Sucampo Pharmaceuticals, Inc. (SCMP) is surging over 10% to $16.52 in pre-market trading Wednesday after it reported fiscal results for the fourth quarter. In its quarterly report, the biopharmaceutical firm said it earned $0.21 per share, non-GAAP, in-line with what Wall Street was expecting. Revenue rose 54.3% on a yoy basis to $37.8 million, but […] View the full post at: Sucampo Pharmaceuticals (SCMP) Misses Q4 Revenue Forecasts Related posts: Rockefeller Institute: State Revenue Report Will Congress back down on stricter rules for Wall Street?